Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 13,685 shares of the business's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $165.87, for a total transaction of $2,269,930.95. Following the transaction, the chief executive officer now directly owns 253,944 shares in the company, valued at approximately $42,121,691.28. The trade was a 5.11 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Steven Leonard Chapman also recently made the following trade(s):
Shares of NTRA traded up $0.65 during midday trading on Friday, hitting $176.92. The company had a trading volume of 1,237,479 shares, compared to its average volume of 1,410,793. The company's 50-day simple moving average is $166.89 and its 200-day simple moving average is $138.14. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a 1 year low of $64.74 and a 1 year high of $183.00. The firm has a market capitalization of $23.36 billion, a P/E ratio of -100.52 and a beta of 1.65.
Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $439.80 million during the quarter, compared to analysts' expectations of $361.43 million. During the same quarter in the previous year, the business posted ($0.95) EPS. The firm's revenue was up 63.9% on a year-over-year basis. As a group, sell-side analysts expect that Natera, Inc. will post -1.56 EPS for the current year.
Large investors have recently bought and sold shares of the business. Global Retirement Partners LLC boosted its position in shares of Natera by 55.0% during the 4th quarter. Global Retirement Partners LLC now owns 434 shares of the medical research company's stock worth $69,000 after acquiring an additional 154 shares in the last quarter. Convergence Investment Partners LLC boosted its holdings in Natera by 41.1% in the fourth quarter. Convergence Investment Partners LLC now owns 2,757 shares of the medical research company's stock valued at $436,000 after purchasing an additional 803 shares in the last quarter. CIBC Asset Management Inc increased its stake in Natera by 5.3% in the fourth quarter. CIBC Asset Management Inc now owns 3,663 shares of the medical research company's stock valued at $580,000 after purchasing an additional 186 shares during the last quarter. State of New Jersey Common Pension Fund D raised its holdings in Natera by 0.8% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 43,584 shares of the medical research company's stock worth $6,899,000 after purchasing an additional 343 shares in the last quarter. Finally, Capital Performance Advisors LLP lifted its position in shares of Natera by 66.8% during the 4th quarter. Capital Performance Advisors LLP now owns 1,655 shares of the medical research company's stock worth $262,000 after buying an additional 663 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.
Several research analysts recently weighed in on NTRA shares. Leerink Partners increased their price objective on Natera from $140.00 to $150.00 and gave the stock an "outperform" rating in a research report on Thursday, October 17th. Sanford C. Bernstein upped their target price on shares of Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a research report on Friday, January 10th. The Goldman Sachs Group increased their target price on shares of Natera from $160.00 to $190.00 and gave the stock a "buy" rating in a research note on Tuesday. Guggenheim boosted their price target on shares of Natera from $170.00 to $200.00 and gave the company a "buy" rating in a research note on Friday, January 17th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, December 13th. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, Natera currently has an average rating of "Moderate Buy" and an average target price of $165.88.
Check Out Our Latest Research Report on NTRA
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.